Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Dec 13;8:2103. doi: 10.1038/s41467-017-02282-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — GAr-dependent induction of E2F1 is mediated via PI3Kδ. a Western blots show the expression of E2F1 in H1299 cells expressing the GAr or EV following treatment with indicated drugs for 8 h. Phosphorylated 4E-BP1 (P-4E-BP1) was used to show mTOR activity. b Western blots show E2F1 expression levels in cells expressing the GAr or control plasmid (EV), treated with the indicated concentrations of inhibitors of PI3K p110δ (CAL-101), p110γ (middle panel) and p110α (lower panel) subunits. c The effect of wortmannin and the PI3Kδ-specific inhibitor (CAL-101) on the phosphorylation of AKT (P-AKT) and 4E-BP1 (P-4E-BP1) in cells treated with 40 ng/ml of PDGF for 30 min in serum-free medium. d Western blots showing the effect of GAr on the phosphorylation of AKT and 4E-BP1. e Western blot showing the expression of E2F1 following 24 h treatment with siRNA against PI3Kδ. f Western blot showing the expression of E2F1 in cells expressing EV or GAr followed by general induction of PI3K activity using MgSO₄ (20 mM) and LPS (1 µg), with, or without, CAL-101 (10 µM). Western blots represent n ≥ 3. Actin was used as a loading control.